All Type of News
‘The domestic biochip market will be worth of KRW 522 billion this year’
While the ‘Biochip’ field has received attention as a basic technology of various industries, such as fundamental research, new drug development and medical equipment, the domestic biochip market is estimated worth of...
The Canadian generic pharmaceutical company ‘Pharmascience’ will enter the Korea market
Co-established by the Canadian generic pharmaceutical company, ‘Pharmascience’, and ‘Kolmar Korea’, ‘Pharmascience Korea’ has got its active business operation.
Morris Goodman, president of Pharmascience, held a pres...
The OchangFactorys invested by Celltrion Pharm with KRW 150 billion will run actively soonThe CelltrionPharm’sOchang Factory has begun to manufacture for this year after finishing the legal process.
According to the Celltrion Pharm on the 21st, the Ochang Factory wa...
|
Multinational pharmaceutical companies chases the new target, ‘OTC drugs’
In the past, ‘multinational pharmaceutical companies’ were recognized to focus on manufacturing ETC (Ethical) drugs, like antibiotics, but it seems that the trend is changing lately.
It is observed that they have exp...
The number of generics per a bioequivalence test was 4 products… the number of the tests went also up
As the regulation to restrict the number of companies participating in a joint or consigned bioequivalence test to 2 companies was abolished, the number of consigned bioequivalence tests increased.
As the result of a...
Samsung begun to acquire the biosimilar of ‘Enbrel’ in EuropeSamsung has pushed ahead to acquire the European approval of the ‘Enbrel’biosmilar.
Samsung Bioepis announced that the European Medicines Agency (EMA) completed reviewing the a...
|
The diabetic treatment ‘Janumet XR’ exceeded the annual sales of KRW 10 billion within a year
The MSD Korea’s (CEO Dong-wook Hyun) DDP-4 inhibitor, the sitagliptin/metformin extended release ‘Janumet XR’, recorded the annual sales of KRW 10.3 billion (based on the UBIST’s outpatient prescription expenses) in 2...
The domestic entry of the biosimilar of Lantus will create a powerful diabetic lineup for BI-Lilly
Boehringer Ingelheim and Lilly (hereinafter referring to BI-Lilly)are about to dominate the diabetic treatment market.
They are preparing entry of the biosimilar product of the Sanofi’s basal insulin release ‘Lantus ...
The Ministry of Health and Welfare will expand the number of medical institutions participating in the telemedicine project to 50
In order to remove medical blind spots this year, the Ministry of Health and Welfare (Minister Hyung-pyo Moon) will expand the number of clinic-level medical institutions participating in the telemedicine project from...
Hanmi and SK will develop generics of Xarelto
It is observed that the generic of the 2nd generation anticoagulant ‘Xarelto’ is being developed.
It is known that the owner company of ‘Xarelto’, Bayer Korea, acquired an approval for the bioequivalence test plan to...
